Thalys Medical Technology Group Inc. (603716.SS)
CNY 10.69
(3.89%)
CNY 10.69
(3.89%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -23.79 Million CNY | -37.87% |
| 2022 | 123.16 Million CNY | -47.71% |
| 2021 | 154.94 Million CNY | -16.5% |
| 2020 | 242.39 Million CNY | -12.1% |
| 2019 | 294.05 Million CNY | 21.01% |
| 2018 | 256.59 Million CNY | 26.09% |
| 2017 | 202.1 Million CNY | 37.89% |
| 2016 | 143.86 Million CNY | 18.65% |
| 2015 | 122.87 Million CNY | 14.38% |
| 2014 | 106.6 Million CNY | 10.7% |
| 2013 | 94.67 Million CNY | 42.46% |
| 2012 | 69.37 Million CNY | 12.8% |
| 2011 | 60.46 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -47.4 Million CNY | -258.58% |
| 2024 Q1 | 32.56 Million CNY | 120.18% |
| 2024 Q2 | 29.23 Million CNY | -9.23% |
| 2023 Q3 | 4.61 Million CNY | -90.27% |
| 2023 FY | - CNY | -37.87% |
| 2023 Q1 | 9.21 Million CNY | 110.45% |
| 2023 Q2 | 47.44 Million CNY | 414.63% |
| 2023 Q4 | -59.47 Million CNY | -1388.34% |
| 2022 Q2 | 29.19 Million CNY | -50.03% |
| 2022 Q1 | 58.43 Million CNY | 72.78% |
| 2022 FY | - CNY | -47.71% |
| 2022 Q4 | -88.21 Million CNY | -323.95% |
| 2022 Q3 | 39.39 Million CNY | 34.9% |
| 2021 Q2 | 35.51 Million CNY | -22.79% |
| 2021 Q3 | 23.92 Million CNY | -32.63% |
| 2021 Q1 | 46 Million CNY | -50.71% |
| 2021 FY | - CNY | -16.5% |
| 2021 Q4 | 33.82 Million CNY | 41.35% |
| 2020 Q2 | 67.23 Million CNY | 793.62% |
| 2020 Q1 | -9.69 Million CNY | -121.84% |
| 2020 FY | - CNY | -12.1% |
| 2020 Q4 | 93.32 Million CNY | 42.9% |
| 2020 Q3 | 65.3 Million CNY | -2.86% |
| 2019 Q2 | 79.02 Million CNY | 63.27% |
| 2019 FY | - CNY | 21.01% |
| 2019 Q3 | 75.11 Million CNY | -4.94% |
| 2019 Q4 | 44.37 Million CNY | -40.92% |
| 2019 Q1 | 48.39 Million CNY | 4.35% |
| 2018 Q3 | 54.79 Million CNY | -9.1% |
| 2018 Q2 | 60.28 Million CNY | 25.88% |
| 2018 Q1 | 47.89 Million CNY | -3.43% |
| 2018 FY | - CNY | 26.09% |
| 2018 Q4 | 46.37 Million CNY | -15.36% |
| 2017 Q4 | 49.59 Million CNY | -13.93% |
| 2017 Q3 | 57.62 Million CNY | 80.59% |
| 2017 Q2 | 31.9 Million CNY | 22.6% |
| 2017 Q1 | 26.02 Million CNY | 16.37% |
| 2017 FY | - CNY | 37.89% |
| 2016 Q3 | 38.74 Million CNY | 37.06% |
| 2016 FY | - CNY | 18.65% |
| 2016 Q4 | 22.36 Million CNY | -42.27% |
| 2016 Q2 | 28.26 Million CNY | -4.92% |
| 2016 Q1 | 29.72 Million CNY | 11.05% |
| 2015 Q4 | 26.76 Million CNY | -1.38% |
| 2015 FY | - CNY | 14.38% |
| 2015 Q3 | 27.14 Million CNY | 0.0% |
| 2014 FY | - CNY | 10.7% |
| 2013 FY | - CNY | 42.46% |
| 2012 FY | - CNY | 12.8% |
| 2011 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 1.11 Billion CNY | 102.136% |
| Joinn Laboratories(China)Co.,Ltd. | 639.51 Million CNY | 103.721% |
| WuXi AppTec Co., Ltd. | 14.16 Billion CNY | 100.168% |
| Autobio Diagnostics Co., Ltd. | 1.87 Billion CNY | 101.271% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 1.33 Billion CNY | 101.787% |
| Chemclin Diagnostics Co., Ltd. | 219.33 Million CNY | 110.848% |